209 results on '"Macchini M"'
Search Results
2. Predictive factors of selective transarterial embolization failure in acute renal bleeding: a single-center experience
3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
4. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
5. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
6. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
7. Percutaneous transluminal angioplasty alone versus stent placement for the treatment of transplant renal artery stenosis
8. EUS-guided Gastroenterostomy for management of malignant Gastric Outlet Obstruction: a prospective series from the PROTECT registry
9. OC.01.1 EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY
10. 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations
11. 1534TiP Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
12. 1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
13. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients
14. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’
15. C28 - Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going?
16. C7 - Evaluation of stromal tumour-infiltrating lymphocytes (TILs) in breast cancer by Dynamic contrast–enhanced magnetic resonance (DCE-MR) imaging
17. 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)
18. PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer
19. 1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)
20. 1664P Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
21. 1635P Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
22. 500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study
23. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors
24. 1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma
25. P-286 Exploring chemotherapy holiday in pancreatic cancer patients responding to upfront nab-paclitaxel-gemcitabine containing regimens
26. Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC
27. Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs?
28. Parasympathetic signaling via Chrm1directly suppresses pancreatic carcinogenesis and cancer stemness through inhibition of EGFR/MAPK and PI3K/AKT pathway
29. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
30. Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going?
31. Evaluation of stromal tumour-infiltrating lymphocytes (TILs) in breast cancer by Dynamic contrast–enhanced magnetic resonance (DCE-MR) imaging
32. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
33. Clinical Impact of Nonselective Beta-Blockers on Survival in Patients with Pancreatic Cancer - Revival of well known drugs?
34. PD-004 - Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC
35. Combined Pre- and Postnatal Minimally Invasive Approach to a Complex Symptomatic Congenital Pulmonary Airway Malformation
36. Einfluss von nicht-selektiven Betablockern auf das Überleben in Pankreaskarzinompatienten – Neue Chance mit gut bekannten Medikamenten?
37. Effects of streptozotocin in the WDHA syndrome not amenable to radical surgery
38. Parasympathische Signalwege unterdrücken die Entstehung und Progression des duktelen Adenokarzinoms des Pankreas
39. Stress beschleunigt die Progression des Pankreaskarzinoms
40. D3 - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
41. 739P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
42. Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment
43. Useful of Choi's criteria after neoadjuvant chemoradiotherapy in patients with resectable pancreatic cancer
44. Prognostic factors for recurrence in resected pancreatic adenocarcinoma: A single-center experience.
45. Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study.
46. Gastroscopy with te fiberscope
47. 98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors
48. Soluzioni Attuali al Problema Terapeutico Dei Tumori Maligni Del Testicolo
49. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
50. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.